ストックスクリーナーアプリを入手
1.52
7.32%
-0.12
アフターアワーズ：
1.50
-0.02
-1.32%
前日終値:
$1.64
開ける：
$1.615
24時間の取引高:
11.59M
Relative Volume:
2.57
時価総額：
$444.30M
収益：
-
当期純損益:
$-63.08M
株価収益率:
-5.6296
EPS:
-0.27
ネットキャッシュフロー:
$-72.53M
1週間 パフォーマンス:
+8.57%
1か月 パフォーマンス:
+46.15%
6か月 パフォーマンス:
+112.68%
1年 パフォーマンス:
+48.29%
1日の値動き範囲:
$1.41
$1.62
1週間の範囲:
$1.31
$1.78
52週間の値動き範囲:
$0.515
$1.78
Ocugen Inc Stock (OCGN) Company Profile
OCGN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.52 | 512.18M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
381.87 | 96.56B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.58 | 60.08B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.51 | 61.15B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
711.09 | 44.66B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
328.71 | 36.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-15 | 開始されました | Maxim Group | Buy |
| 2023-03-01 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | 開始されました | Mizuho | Buy |
| 2022-06-15 | 再開されました | ROTH Capital | Buy |
| 2022-06-02 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-07-26 | 開始されました | Noble Capital Markets | Outperform |
| 2021-06-11 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2021-05-07 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | アップグレード | H.C. Wainwright | Neutral → Buy |
すべてを表示
Ocugen Inc (OCGN) 最新ニュース
Ocugen, Inc. Hits New 52-Week High at $1.78, Marking Significant Milestone - Markets Mojo
Ocugen (NASDAQ:OCGN) Reaches New 52-Week HighTime to Buy? - MarketBeat
Ocugen Shares Surge as Strategic Shift Renews Investor Confidence - AD HOC NEWS
200,100 Shares in Ocugen, Inc. $OCGN Acquired by Procyon Advisors LLC - MarketBeat
Ocugen's (OCGN) Buy Rating Reaffirmed at Chardan Capital - MarketBeat
Ocugen (NASDAQ:OCGN) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Ocugen: A Retinal Disease Juggernaut In The Making (NASDAQ:OCGN) - Seeking Alpha
Ocugen Strikes $187.5 Million Licensing Deal With Kwangdong for Gene Therapy in Korea - MSN
Why Ocugen Stock Zoomed 12% Higher Today - MSN
Why Ocugen (OCGN) Is Up 25.2% After Securing Korean Rights for Gene Therapy OCU400 - simplywall.st
Valuation Update: Can Ocugen Inc. weather a recessionJuly 2025 Analyst Calls & Precise Buy Zone Identification - خودرو بانک
How does Ocugen Inc. score in quality rankingsEarnings Summary Report & Weekly Sector Rotation Insights - khodrobank.com
Maxim Group Maintains Ocugen(OCGN.US) With Buy Rating, Maintains Target Price $4 - 富途牛牛
Nasdaq Moves: Is Ocugen Inc a momentum stock2025 Earnings Surprises & Reliable Intraday Trade Plans - خودرو بانک
Ocugen gets EU approval for Prolia and Xgeva biosimilars (OGN:NYSE) - Seeking Alpha
Ocugen (OCGN) Rating and Price Target Maintained by Chardan Capi - GuruFocus
Aug PreEarnings: Whats the MACD signal for Ocugen Inc2025 Stock Rankings & AI Forecast Swing Trade Picks - خودرو بانک
Ocugen Faces Merger Termination with Carisma Therapeutics - TipRanks
Malvern-Based Ocugen Secures Multimillion Dollar Licensing Deal with Korean Pharma Giant - VISTA.Today
Ocugen merger agreement with Carisma terminated due to funding shortfall By Investing.com - Investing.com Australia
Ocugen Enters Subscription Agreement with Carisma Therapeutics - MSN
Ocugen merger agreement with Carisma terminated due to funding shortfall - Investing.com
Analyst Upgrade: Is Ocugen Inc. stock a smart retirement pickJuly 2025 Action & Accurate Buy Signal Alerts - خودرو بانک
Ocugen Inc says on Sept 16, carisma terminates merger agreement with Ocugen - MarketScreener
Carisma's lifeline dissipates as reverse merger plans fall through, Moderna cuts ties - Fierce Biotech
Ocugen (OCGN): Evaluating Valuation Following Exclusive Korean Licensing Deal for Gene Therapy OCU400 - Yahoo Finance
Highs Report: Is MSCI Inc. stock a good pick for beginnersJuly 2025 Opening Moves & Fast Momentum Stock Entry Tips - خودرو بانک
Aug Movers: Is Ocugen Inc a cyclical or defensive stockMarket Performance Report & Safe Entry Point Identification - خودرو بانک
Analysis Recap: Is Ocugen Inc. forming bullish engulfing patternsMarket Sentiment Report & Weekly High Potential Stock Alerts - خودرو بانک
Setup Watch: Can Ocugen Inc be recession proofStop Loss & Precise Buy Zone Identification - خودرو بانک
Panic Selling: What is the next catalyst for Ocugen IncWeekly Market Report & High Conviction Investment Ideas - خودرو بانک
Ocugen Announces Q2 2025 Financial Results Call and Business Update - MSN
Weekly Recap: How cyclical is Comtech Telecommunications Corps revenue streamFed Meeting & AI Powered Buy/Sell Recommendations - khodrobank.com
Ocugen Signs Exclusive License Agreement with Kwangdong - TipRanks
Gains Recap: What is the next catalyst for Mattel IncDay Trade & Reliable Price Action Trade Plans - خودرو بانک
Ocugen, Kwangdong complete licensing agreement for OCU400 gene therapy in Korea - Modern Retina
Why Ocugen (OCGN) Is Up 16.5% After Licensing OCU400 Gene Therapy Rights to Kwangdong - Yahoo Finance
Ideas Watch: Is Ocugen Inc undervalued by DCF analysisWeekly Volume Report & Expert Curated Trade Setup Alerts - khodrobank.com
Published on: 2025-09-16 04:47:37 - khodrobank.com
Big Money Moves: Is Ocugen Inc showing insider buyingQuarterly Performance Summary & Weekly Momentum Stock Picks - خودرو بانک
Ocugen (OCGN) Stock Rises on South Korea Licensing Deal - GuruFocus
Ocugen Inc. stock rises Monday, outperforms market - AllSides
Ocugen Shares Are Trading Higher Monday: What's Going On? - Benzinga
Ocugen shares soar on gene therapy deal with Korean pharma giant - The Business Journals
Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea - Ocugen
Ocugen and Kwangdong complete licensing agreement for OCU400 gene therapy in Korea - Ophthalmology Times
Ocugen (OCGN) Secures Licensing Deal with Kwangdong for Gene Therapy in Korea - GuruFocus
Ocugen, Inc. Announces Licensing Agreement with Kwangdong Pharmaceutical for OCU400, Potentially Worth Up to $187.5 Million - Quiver Quantitative
Ocugen Inc (OCGN) 財務データ
収益
当期純利益
現金流量
EPS
2.43%
大文字化:
|
ボリューム (24 時間):